Latest news with #Bullpen
Associated Press
2 days ago
- Business
- Associated Press
Bullpen Launches Emerging Fund to Champion the Next Generation of Life Sciences Innovators
New investment initiative fuels high-potential startups across biotools, medtech, digital health, and therapeutics. 'BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships.'— Christiaan Engstrom, CEO of Bullpen. BOSTON, MA, UNITED STATES, June 4, 2025 / / -- Bullpen, a trusted community of life sciences dealmakers, today announced the launch of its Bullpen Emerging Fund, a bold initiative designed to back mission-driven startups that are redefining the future of health. Through capital investment, deep mentorship, and access to a close-knit network of expert operators and investors, the fund aims to turn today's early-stage breakthroughs into tomorrow's clinical realities. The Emerging Fund, available to accredited investors, invests in standout companies selected for Bullpen's On-Deck class—founders chosen not only for their science but for their grit, vision, and purpose. The 2025 cohort includes: - Chandima Bandaranayaka, CEO: Precision Quantomics, accelerating drug discovery and personalized pharmacotherapy through high-resolution molecular profiling. - David Mead, CEO: Terra Bioforge, harnessing synthetic biology to streamline biological production and accelerate therapeutic development. - Doug Cohen, CEO: IR Medtek, developing real-time, noninvasive cancer detection technologies that improve early diagnosis and patient outcomes. - Harsha Rajasimha, CEO: Jeeva Clinical Trials, delivering decentralized trial software that enhances patient access, retention, and diversity in clinical research. - Linda Tempelman, CEO: Persista Bio, advancing cell therapy solutions for chronic diseases, including a novel approach to treating Type 1 diabetes. Each of these founders will pitch during Bullpen's 'Money Ball' sessions, June 16–18 at BIO International, to an audience of mission-aligned investors and partners. More than a moment on stage, these pitches represent the culmination of rigorous preparation and the start of a meaningful growth journey. 'Bullpen was built on a simple idea: if you bring the right people together in the right way, the outcomes take care of themselves. BIO Week is our opportunity to strip away the noise and create a space where life science leaders can connect authentically, share candid insights, and forge the partnerships that will move this industry forward,' said Christiaan Engstrom, CEO of Bullpen. Further information on the Bullpen Emerging Fund may be obtained from Ray Jordan, managing director, Putnam Insights LLC, and initial investor in the fund through Elmstead Partners LLC. Jordan may be reached at [email protected]. Expert Coaching to Catalyze Success Behind each founder is a seasoned mentor: - Michael Hill, Global Head of Science Innovations, MedTech Head Coach, with a legacy of scaling clinical tools from bench to bedside. - Stella Vnook, CEO of Likarda and Therapies Head Coach, a biotech operator with deep experience in moving science-backed products through commercial launch. - John Bonham-Carter, BioTools Head Coach and angel investor, guiding early-stage science into successful enterprise with strategic insight and operational depth. Throughout the week, Bullpen will host engaging programming across Boston innovation hubs like Portal Innovations, SmartLabs, and EPAM Continuum. Key agenda highlights include: Agenda Highlights Include: - Investor interviews with leaders from Novo Nordisk, Cincytech, DigitalDx, Mayo Clinic, Riverside Partners, and others, with open Q&A in the Press Room following each session. - Thematic forums exploring pivotal industry issues such as: - AI in Healthcare: Exploring how artificial intelligence is reshaping patient care and discovery. - Patient Access: Breaking down barriers to get therapies to those who need them most. - Tech Transfer: Bridging academic science and commercial application. - Rare Disease: Elevating patient voices and rare innovation journeys. - Global Forums: Perspectives from Japan, Korea, Canada, and Australia spotlighting international innovation. - Women in VC and venture insights sessions, giving voice to underrepresented perspectives in capital formation and funding trends. As BIO Week wraps, Bullpen leaves behind more than a schedule, it strengthens a movement. One that champions science, centers people, and dares to do things differently. With the Emerging Fund as its catalyst, Bullpen is helping the next generation of health innovators go further, faster. About Bullpen: Founded on the mantra Find Someone to Help. Repeat., Bullpen is a volunteer-led, member-driven network designed to foster meaningful connections and accelerate innovation in life sciences. With no booths or sales pitches, Bullpen cultivates a space where authentic conversation drives real outcomes. Its members include public and private company leaders, VCs, strategics, accelerators, and non-profit executives dedicated to building the future of health. Media Inquiries: Madelyn De Los Santos Putnam Insights email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
CNBC
4 days ago
- Business
- CNBC
One stock we might need to buy on the dip and another Cramer would buy big now
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Monday's key moments. The S & P 500 fell on the first trading day of June after a weekend of no progress on China trade talks. In fact, China refuted President Donald Trump 's accusation Friday morning that Beijing violated its trade agreement with the U.S. The White House on Monday said Trump will likely talk with Chinese President Xi Jinping this week. "I think the Chinese would be nuts to make a deal," Jim Cramer said during the Morning Meeting. "China does not seem to have as much to lose as we think." In Jim's Sunday column , he looked at how the president's tariff unpredictability is holding back the market in 10 ways. Late Friday, at a rally in Pennsylvania, the president said he's doubling the tariff rate on steel to 50%, starting June 4. Shares of steelmaker and miner Cleveland-Cliffs on Monday jumped more than 25% on the news, while rival Nucor , which is in our Bullpen, gained more than 10%. Steel tariffs, in theory, can even the global playing field on price. Companies that make steel and service the domestic industry may benefit in the near term, but what about industrials that rely on steel as an input cost? Many of them are down Monday, including Club name Dover, which has some steel exposure. "We might have to go pick at this one," Jim said. "I think that's way too low." "Let's go to something I find actionable in our portfolio that I do not get," Jim said. "The action is Capital One." The Club stock, which was down Monday with the banks, has not been rewarded for its Discover acquisition. Goldman Sachs put Capital One on its conviction list. "When I worked at Goldman, I would have picked up the phone and told everybody they have to be in this stock," Jim said. To investors without positions in Capital One, "I would be a huge buyer of this thing," Jim said. The benefits of the acquisition are "intrinsic and excellent," Jim said, noting the catalyst of Discover's payment network and the prospects for second-half stock buybacks. Stocks covered in Monday's rapid fire at the end of the video were Campbell's , Bullpen name Boeing , and Club name GE Vernova . (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
CNBC
08-05-2025
- Business
- CNBC
Stocks climb on trade optimism. Here's why Boeing and Goldman are having especially strong days
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets Rally: Stocks surged on Thursday, climbing even further during President Donald Trump's press conference announcing a trade deal with the United Kingdom. The rally, which was broad-based and led by sectors such as energy, industrials, banks, and consumer discretionary, gained momentum as additional details on the deal framework became public — a possible sign that investors are optimistic about reduced trade barriers and increased market access. One deal highlight that was most interesting to us was the U.K.'s agreement to buy airplane parts, most notably a $10 billion "Boeing procurement." This development confirms the logic behind our decision last month to add Boeing to our Bullpen , based on the thesis that its planes could be used to reduce bilatiral trade deficits between the U.S. and its trading partners. Shares of Boeing added more than 3% Thursday. Trump also struck an upbeat tone that this weekend's planned talks between Treasury Secretary Scott Bessent, U.S. Trade Rep. Jamieson Greer, and Chinese officials will be "substantive" and could lead to tariffs rates coming down. Goldman talk: One of the best-performing Club stocks Thursday is Goldman Sachs , with shares rising roughly 3%. Investment banking rival Morgan Stanley , which we no longer own, also is having a strong day. What's driving the outperformance? Investors may be betting that the U.K. trade deal means more are on the way — and by extension, a lot of the uncertainty that crimped dealmaking activity at the start of the year could start to subside. We got a chance to hear Goldman's president and chief operating officer, John Waldron, discuss the backdrop for deals earlier Thursday in an interview on CNBC. John Waldron offered plenty of good insight on mergers and acquisitions and initial public offerings, so it's worth reading them at length. "I think we can actually get back to a reasonable capital markets level of activity because ... the backlog and pipeline remains very, very strong," Waldron said. "I think there's fundamental demand for those capital markets transactions with a little bit more of a certain backdrop." CNBC's Carl Quintanilla then asked Waldron whether M & A or IPOs would see the rebound first. "Well, I think M & A is healthier," Waldron responded. "I think there's a fair bit of demand for M & A. I think scale is still a big underlying driver of M & A. Technology spend, need to really create breadth and operating leverage in your business. So, I think there's really good underpinnings for M & A. IPOs are harder because IPOs are really the riskier element of what market participants will express as a point of view. So, I think IPOS probably lag. ... Those in [in the media] love to talk about the capital markets decline. And volumes in April were obviously down meaningfully. But if you look at it in the round, we've actually had a reasonable year thus far, and I think if we get a little bit of a more certain underpinning, we could end up having a good end of the year and the second half could be strong. But we definitely need a stronger underlying economic footing to get there." Funny enough, Reuters reported shortly after the interview that the U.S. corporate travel and expense company Navan has hired underwriters for an IPO that could value the company at more than $8 billion. Goldman Sachs was selected as the lead underwriter. Up next: Club name Texas Roadhouse reports after the closing bell Thursday, giving us a closer look at how its comparable store sales fared after the weather disrupted start to the first quarter. Margins will be in focus, especially management's thoughts on beef prices through the rest of the year. Other companies reporting Thursday are Coinbase , Lyft , Paramount Global , Expedia , Affirm , Solventum , Toast , Cloudflare , and DraftKings . There are no major earnings or economic reports Friday. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED. Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street.
